Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological confirmed diagnosis of relapsed intracranial GB
Progressive Disease (PD) following standard chemoradiation
Prior surgical resection allowed
Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1
Adequate hematologic, hepatic and renal function
Discontinued all prior cancer treatments for cancer \& recovered from the acute effects of therapy
Tumor specimen must be available for a central pathology review and prognostic and predictive biomarker evaluation
You may not be if
Moderate or severe heart disease based on New York Heart Association (NYHA) criteria
Prior nitrosurea therapy (including lomustine or Gliadel)
Prior bevacizumab as 1st line treatment for GB (if treatment was concluded 12 months prior to enrollment, the patient may be eligible to participate in the trial)
Current acute or chronic myelogenous leukemia
Second primary malignancy that may affect the interpretation of results